Recruiting PHASE2 INTERVENTIONAL 3-arm NCT06300463

Platform Study of Immunotherapy Combinations in Colorectal Cancer Liver Metastases

Sponsor: Agenus Inc.

Conditions Colorectal Cancer Colorectal Cancer Metastatic Liver Metastases

Interventions AGEN1423 Balstilimab Botensilimab Radiation

Updated 6 times since 2024 Last updated: Apr 4, 2025 Started: Mar 26, 2024 Primary completion: Sep 30, 2026 Completion: Mar 31, 2027

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Colorectal Cancer and Colorectal Cancer Metastatic, this trial is actively recruiting participants. The trial is conducted by Agenus Inc. and has accumulated 6 data snapshots since 2024. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

6 versions recorded

May 2025 — Present [monthly]

Recruiting PHASE2
Apr 2025 — May 2025 [monthly]

Recruiting PHASE2
Sep 2024 — Apr 2025 [monthly]

Recruiting PHASE2
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE2
May 2024 — Jul 2024 [monthly]

Recruiting PHASE2

▶ Show 1 earlier version

Apr 2024 — May 2024 [monthly]

Recruiting PHASE2

First recorded

Mar 2024

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Agenus Inc.
Weill Medical College of Cornell University

Data source: Weill Medical College of Cornell University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• New York, United States